Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ranks among the best biotech stocks to buy. On September 17, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) revealed the findings of its Phase 2 COURAGE trial, which demonstrated that semaglutide and trevogrumab together preserved lean muscle mass while treating obesity with weight loss.
According to the 26-week trial, semaglutide by itself resulted in a 33% of weight loss to come from lean mass loss. In patients treated with semaglutide, around half of the muscle mass that would have been lost was preserved when trevogrumab, an anti-GDF8/anti-myostatin antibody, was introduced.
The study’s weight-loss phase results were reported at the European Association for the Study of Diabetes meeting. In the meantime, patients will continue in a weight maintenance phase through week 52.
Regeneron Pharmaceuticals, Inc. is a prominent biopharmaceutical company that discovers, develops, and commercializes medicines for a variety of diseases, including cancer, eye disorders, and allergies.
READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.
This article is originally published at Insider Monkey.
